Elevated C-reactive protein levels and cardiovascular risk in prurigo nodularis patients with sleep disturbance: a multi-center cohort study
- PMID: 39644366
- DOI: 10.1007/s00403-024-03566-0
Elevated C-reactive protein levels and cardiovascular risk in prurigo nodularis patients with sleep disturbance: a multi-center cohort study
Abstract
Patients with prurigo nodularis (PN) present with pruritus which may lead to sleep disturbances and systemic comorbidities. The objective of our study was to determine the risk of sleep disorders in PN and its association with systemic inflammation and adverse cardiovascular outcomes. We conducted a retrospective population-level cohort using a global health records database to analyze the development of sleep disorders, C-reactive protein (CRP) levels, and risk of cardiovascular disease and mortality in PN compared to controls. PN patients had increased risk of general sleep disorders (RR 1.47, 95%CI 1.42-1.52, obstructive sleep apnea (1.61, 1.54-1.69), insomnia (1.37, 1.29-1.45), hypersomnia (1.47, 1.32-1.64), and restless legs syndrome (1.45, 1.28-1.65). Additionally, PN with sleep disorders had higher CRP levels than PN without sleep disorders (16.2 mg/L vs. 10.6 mg/L). PN patients with sleep disorders were more likely to develop cardiovascular comorbidities, including type 2 diabetes mellitus (RR 2.45, 95%CI 2.25-2.66), metabolic syndrome (4.16, 3.31-5.22), myocardial infarction (2.87, 2.52-3.22), venous thromboembolism (2.93, 2.55-3.39), and greater mortality (HR 1.47, 95%CI 1.34-1.62) compared to PN patients without sleep disorders. Our findings suggest that PN patients are at greater risk of developing various sleep disorders that are associated with adverse cardiovascular outcomes.
Keywords: C-reactive protein; Cardiovascular; Inflammation; Itch; Prurigo nodularis; Pruritus; Sleep.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. IRB status: Waived. Patient consent: Not applicable. Competing interests: The authors declare no competing interests.
References
-
- Kwatra SG (2022) Prurigo Nodularis. JAMA Dermatol 158. https://doi.org/10.1001/jamadermatol.2021.5307
-
- Whang KA, Le TK, Khanna R et al (2022) Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol 86. https://doi.org/10.1016/j.jaad.2021.05.036
-
- Aggarwal P, Choi J, Sutaria N et al (2021) Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol 46. https://doi.org/10.1111/ced.14722
-
- Sutaria N, Alphonse MP, Marani M et al (2022) Cluster analysis of circulating plasma biomarkers in Prurigo Nodularis reveals a distinct systemic inflammatory signature in African americans. J Invest Dermatology 142. https://doi.org/10.1016/j.jid.2021.10.011
-
- Belzberg M, Alphonse MP, Brown I et al (2021) Prurigo Nodularis is characterized by systemic and cutaneous T helper 22 Immune polarization. J Invest Dermatology 141. https://doi.org/10.1016/j.jid.2021.02.749
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
